Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3123)	12/28/2010 12:15:20 PM
From: Jibacoa	Respond to of 3722

RPRX has had a some movements today.<g> It started to the downside, but it recovered soon after the opening and was up 18.51% at its H, and it is now up 7.69% with volume > 7M about 11.5x its ADV. bigcharts.marketwatch.com RPRX reported today that it has submitted to the FDA a reanalysis of the previously completed 200 subject trial ZA-003 of Androxal in the treatment of secondary hypogonadism. It had contracted an outside statistician, Tony Orlando, Ph.D., V.P. of Global Data Division, Pharm-Olam International Ltd., to conduct the analysis.<g> Dr. Orlando performed several different analyses. He checked the results on some small subset groups and also performed a “completer” analysis for all the men in the study.<g> He also looked at the impact of Androxal and Androgel on luteinizing hormone and follicle stimulating hormone in the men with baseline morning testosterone = 250 ng/dl. Androxal significantly increased LH levels in a dose dependent manner. (LH stimulates the testes to produce testosterone.)<g> Androxal also significantly increased FSH in a dose dependent manner. (FSH stimulates the testes to produce sperm.)<g> He also was able to determine that there was a statistically significant correlation between changes in LH and changes in morning testosterone level (correlation = 0.6137, p value <0.0001). This analysis underscores the mode of action of Androxal which restores pituitary responsiveness to low circulating levels of testosterone, in turn stimulating the testes to produce normal levels of testosterone in a normal rhythmic pattern.<g> Joseph S. Podolski, President and CEO of RPRXe, commented, “We believe Dr. Orlando’s observations bode well for our upcoming PIIb and further reinforce the findings from our previous studies.” <g> At any rate, and as previously commented, it seems worth to keep an eye on RPRX, its PIIb and Dr. Orlando's analysis of the data that will be coming, since although the ACTAY on RPRX is only $6, with some good news it has plenty of room to run.<g> bigcharts.marketwatch.com Bernard